Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 12/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962784 | 0.95 | MAPK7 (0.45) | POLBMAPK7PDK2AURKAAURKB | |
| SCHEMBL4962836 | 0.88 | MAPK7 (0.45) | POLBMAPK7PDK2 | |
| SCHEMBL3570253 | 0.86 | POLB (0.44) | POLBMAPK7PDK2TNK2AURKA | |
| SCHEMBL4966596 | 0.85 | MAPK7 (0.46) | MAPK7PDK2 | |
| SCHEMBL5138448 | 0.85 | MAPK7 (0.49) | POLBMAPK7AURKAAURKB | |
| SCHEMBL12048996 | 0.85 | PDGFRB (0.44) | POLBMAPK7AURKAAURKBKIT | |
| SCHEMBL12049062 | 0.84 | KIT (0.42) | POLBMAPK7AURKAAURKBKIT | |
| SCHEMBL4966196 | 0.84 | MAPK7 (0.45) | POLBMAPK7KIT | |
| SCHEMBL3561074 | 0.84 | MAPK7 (0.46) | MAPK7PDK2 | |
| SCHEMBL4963499 | 0.83 | MAPK7 (0.52) | MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893598-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135721-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | POLB 2073/4885MAPK7 489/4885PDK2 1147/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | POLB 1770/4885MAPK7 957/4885PDK2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.